Genitourinary Cancers InvestigatorsMichael L. Blute, MD
John J. Coen, MD
W. Scott McDougal, MD
Douglas M. Dahl, MD
Jason Efstathiou, MD, DPhil
Adam Scott Feldman, MD, MPH
Mukesh G. Harisinghani, MD
Niall M. Heney, MB, MD
Michael E. Hurwitz, MD, PhD
Othon Iliopoulos, MD
Donald S. Kaufman, MD
Richard Lee, MD, PhD
Francis J. McGovern, MD
M. Dror Michaelson, MD, PhD
Aria F. Olumi, MD
William U. Shipley, MD
Mathew R. Smith, MD, PhD
Shahin Tabatabaei, MD
James A. Talcott, MD
Matthew S. Wszolek, MD
Chin-Lee Wu, MD, PhD
Robert H. Young, MD
Anthony L. Zietman, MD
Prostate cancer is the most common noncutaneous malignancy and a leading cause of cancer death in men worldwide. In the United States, more than 220,000 men are diagnosed with prostate cancer annually and approximately 27,000 die from advanced disease. The goals of the Centers clinical research program in prostate cancer are to improve outcomes for men with early stage prostate cancer, develop novel therapies for recurrent and metastatic disease, and improve the quality of life for prostate cancer survivors.
Improve outcomes for men with early stage prostate cancer to:
Develop novel therapies for recurrent and metastatic disease:
Improve the quality of life for prostate cancer survivors:
Transitional cell carcinoma of the urinary bladder is a leading cause of cancer death. In the United States, more than 67,000 men and women are diagnosed with bladder cancer annually and approximately 13,750 die from the disease. The spectrum of transitional cell carcinoma includes superficial, invasive, and metastatic disease, each with its own clinical presentation, prognosis, and treatment. The goals of the Centers' clinical research program in bladder cancer are to develop innovative strategies to treat invasive bladder cancer and to evaluate biologic predictors of cancer outcomes.
Develop innovative strategies to treat invasive bladder cancer:
Renal cell carcinoma or kidney cancer is a devastating malignancy that is responsible for more than 13,000 deaths per year in the United States. Most early stage renal cell carcinomas are successfully treated with surgery. Prognosis for patients with metastatic disease is generally poor, but advances in understanding the biology or renal cell carcinoma and antiangiogenic therapy have revolutionized the treatment of advanced renal cell carcinoma. The goals of the Centers clinical research program in renal cell carcinoma are to optimize the treatment for early stage renal cell carcinoma and to develop novel therapeutic approaches to treat advanced stage disease.
Optimize the treatment for early stage renal cell carcinoma:
Develop novel therapeutic approaches to treat advanced stage renal cell carcinoma:
Vertebral fractures in men receiving androgen-deprivation therapy for prostate cancer are associated with pain, loss of mobility, and decreased survival.
1 Smith MR, Lee H, Nathan DM
Insulin sensitivity during combined androgen blockade for prostate cancer.
J Clin Endocrinol Metab. 04/07/2006; 91(4); 1305-8.
2 Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.
Cancer. 12/10/2007; 110(12); 2691-9.
3 Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
Cancer. 05/05/2008; 112(10); 2188-94.
4 Michaelson MD, Smith MR, Talcott JA
Prostate cancer (metastatic).
Clin Evid. 11/23/2004; (10) 1012-22.
5 Clark JA, Talcott JA
Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made.
J Clin Oncol. 09/19/2006; 24(27); 4457-63.
6 Talcott JA
Prostate cancer quality of life: beyond initial treatment and the patient.
J Clin Oncol. 09/19/2007; 25(27); 4155-6.